JP6518197B2 - バース症候群の予防または治療のための方法及び組成物 - Google Patents

バース症候群の予防または治療のための方法及び組成物 Download PDF

Info

Publication number
JP6518197B2
JP6518197B2 JP2015560377A JP2015560377A JP6518197B2 JP 6518197 B2 JP6518197 B2 JP 6518197B2 JP 2015560377 A JP2015560377 A JP 2015560377A JP 2015560377 A JP2015560377 A JP 2015560377A JP 6518197 B2 JP6518197 B2 JP 6518197B2
Authority
JP
Japan
Prior art keywords
subject
acid
taz1
peptide
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015560377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016511259A5 (enExample
JP2016511259A (ja
Inventor
ディー トラヴィス ウィルソン
ディー トラヴィス ウィルソン
マーク バンバーガー
マーク バンバーガー
Original Assignee
ステルス バイオセラピューティックス コープ
ステルス バイオセラピューティックス コープ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ステルス バイオセラピューティックス コープ, ステルス バイオセラピューティックス コープ filed Critical ステルス バイオセラピューティックス コープ
Publication of JP2016511259A publication Critical patent/JP2016511259A/ja
Publication of JP2016511259A5 publication Critical patent/JP2016511259A5/ja
Priority to JP2019080101A priority Critical patent/JP6918046B2/ja
Application granted granted Critical
Publication of JP6518197B2 publication Critical patent/JP6518197B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2015560377A 2013-03-01 2014-02-28 バース症候群の予防または治療のための方法及び組成物 Active JP6518197B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019080101A JP6918046B2 (ja) 2013-03-01 2019-04-19 バース症候群の予防または治療のための方法及び組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361771642P 2013-03-01 2013-03-01
US201361771534P 2013-03-01 2013-03-01
US61/771,534 2013-03-01
US61/771,642 2013-03-01
US201361839753P 2013-06-26 2013-06-26
US61/839,753 2013-06-26
PCT/US2014/019622 WO2014134554A1 (en) 2013-03-01 2014-02-28 Methods and compositions for the prevention or treatment of barth syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019080101A Division JP6918046B2 (ja) 2013-03-01 2019-04-19 バース症候群の予防または治療のための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2016511259A JP2016511259A (ja) 2016-04-14
JP2016511259A5 JP2016511259A5 (enExample) 2017-04-06
JP6518197B2 true JP6518197B2 (ja) 2019-05-22

Family

ID=51428869

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015560377A Active JP6518197B2 (ja) 2013-03-01 2014-02-28 バース症候群の予防または治療のための方法及び組成物
JP2019080101A Active JP6918046B2 (ja) 2013-03-01 2019-04-19 バース症候群の予防または治療のための方法及び組成物
JP2021019903A Active JP7072692B2 (ja) 2013-03-01 2021-02-10 バース症候群の予防または治療のための方法及び組成物
JP2022077425A Active JP7381652B2 (ja) 2013-03-01 2022-05-10 バース症候群の予防または治療のための方法及び組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019080101A Active JP6918046B2 (ja) 2013-03-01 2019-04-19 バース症候群の予防または治療のための方法及び組成物
JP2021019903A Active JP7072692B2 (ja) 2013-03-01 2021-02-10 バース症候群の予防または治療のための方法及び組成物
JP2022077425A Active JP7381652B2 (ja) 2013-03-01 2022-05-10 バース症候群の予防または治療のための方法及び組成物

Country Status (9)

Country Link
US (5) US9687519B2 (enExample)
EP (2) EP2961420B1 (enExample)
JP (4) JP6518197B2 (enExample)
CN (3) CN115990242A (enExample)
CA (1) CA2916880C (enExample)
DK (1) DK2961420T3 (enExample)
ES (1) ES2750258T3 (enExample)
HU (1) HUE046924T2 (enExample)
WO (1) WO2014134554A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2788013A4 (en) * 2011-12-09 2015-08-19 Stealth Peptides Int Inc AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
CN117752766A (zh) 2013-03-01 2024-03-26 康德生物医疗有限公司 治疗线粒体疾病的方法
CN115990242A (zh) * 2013-03-01 2023-04-21 康德生物医疗有限公司 预防或治疗巴斯综合征的方法和组合物
WO2014209905A2 (en) * 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods and compositions for detecting and diagnosing diseases and conditions
US9550981B2 (en) 2014-01-22 2017-01-24 University Of Washington Modified tafazzin proteins and methods of making and using the same
EP3230308B1 (en) 2014-12-12 2019-05-01 University of Washington Methods for treating and preventing cardiomyopathy
WO2018104172A1 (en) 2016-12-06 2018-06-14 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating barth syndrome
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
JP7606966B2 (ja) * 2018-12-18 2024-12-26 ステルス バイオセラピューティクス インコーポレイテッド ミトコンドリア病を標的とするアナログ

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
CA2457391A1 (en) 2001-08-06 2003-02-20 Vanderbilt University Device and methods for detecting the response of a plurality of cells to at least one analyte of interest
BRPI0105509B8 (pt) 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
EP2865385B1 (en) 2003-02-04 2016-11-16 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
SI1599216T1 (sl) 2003-02-04 2014-02-28 Cornell Research Foundation, Inc. Postopek za preprečevanje mitohondrijskega permeabilnostnega prehoda
AU2004210013A1 (en) * 2003-02-10 2004-08-19 Autogen Research Pty Ltd Therapeutic molecules
WO2005023274A1 (en) 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
CA2971928C (en) 2004-01-23 2019-01-08 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US8500720B2 (en) 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
US20070265216A1 (en) * 2005-10-05 2007-11-15 Gross Richard W Enhanced medical treatment in diabetic cardiomyopathy
AU2007237899A1 (en) 2006-04-18 2007-10-25 Cortendo Invest, Ab Methods and compositions for treating barth syndrome, cardiomyopathy, mitochondrial diseases and other conditions
WO2008137035A1 (en) 2007-05-02 2008-11-13 The Mclean Hospital Corporation Methods and compositions for mitochondrial replacement therapy
US20080318909A1 (en) 2007-06-14 2008-12-25 Sparagna Genevieve C Use Of Linoleic Compounds Against Heart Failure
WO2008156654A2 (en) 2007-06-15 2008-12-24 Massachusetts Institute Of Technology Cytoskeleton modulators for treating metabolic disorders
JP5677096B2 (ja) 2008-02-26 2015-02-25 コーネル ユニヴァーシティー 急性腎障害を予防および治療するための方法
WO2009149307A2 (en) 2008-06-04 2009-12-10 San Diego State University Research Foundation Compositions and methods for restoring mitochondrial electron transfer function
EP2318433A4 (en) 2008-08-07 2012-08-08 Ipsen Pharma Sas GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE ANALOGUES (GIP) MODIFIED AT THE N-TERMINAL END
EP3563862B1 (en) 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
US20120122957A1 (en) 2009-04-17 2012-05-17 The Salk Institute For Biological Studies Regulation of aging by modulation of mitochondrial function
US20120046363A1 (en) 2009-05-11 2012-02-23 University Of Maryland, Baltimore Docosahexaenoic acid for the treatment of heart failure
CN105031605A (zh) 2009-08-12 2015-11-11 康奈尔大学 预防或治疗代谢综合症的方法
EP3150215A1 (en) * 2009-08-24 2017-04-05 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
CN102711785A (zh) 2009-10-05 2012-10-03 康奈尔大学 预防或治疗心力衰竭的方法
EP2519232A1 (en) 2009-12-31 2012-11-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
CN103751763A (zh) 2009-12-31 2014-04-30 康肽德生物医药技术有限公司 用于预防或治疗血管阻塞损伤的方法
US8719939B2 (en) 2009-12-31 2014-05-06 Mcafee, Inc. Malware detection via reputation system
JP4643749B1 (ja) 2010-02-03 2011-03-02 昭和電工株式会社 表面被覆サーメット部材の耐酸化膜形成用の処理液
WO2011106717A1 (en) 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3560508A1 (en) * 2010-03-15 2019-10-30 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
EP3290433A1 (en) 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
WO2012009171A2 (en) 2010-07-15 2012-01-19 The Schepens Eye Research Institute, Inc. Compositions and methods of treatment of corneal endothelium disorders
US20140031432A1 (en) 2010-08-06 2014-01-30 Ampere Life Sciences, Inc. Treatment of mitochondrial diseases with vitamin k
US20130345312A1 (en) 2010-08-06 2013-12-26 Orion D. Jankowski Treatment of mitochondrial diseases with naphthoquinones
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
EP3488941A1 (en) * 2011-03-24 2019-05-29 Cornell University Aromatic-cationic peptides and uses of same
CN107496899A (zh) 2011-09-29 2017-12-22 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
WO2013059071A1 (en) 2011-10-17 2013-04-25 Cornell University Aromatic-cationic peptides and uses of same
KR20190077124A (ko) * 2011-10-21 2019-07-02 스템제닉스 인코포레이티드 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자
EP3078384A1 (en) 2012-02-22 2016-10-12 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
WO2013126775A1 (en) * 2012-02-23 2013-08-29 Cornell University Aromatic-cationic peptides and uses of same
WO2014059029A1 (en) 2012-10-09 2014-04-17 President And Fellows Of Harvard College Treatment of age-related and mitochondrial diseases by inhibition of hif-1 alpha function
MX2015005102A (es) 2012-10-22 2016-02-09 Stealth Peptides Int Inc Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociado con el mismo.
CN115990242A (zh) * 2013-03-01 2023-04-21 康德生物医疗有限公司 预防或治疗巴斯综合征的方法和组合物
CN117752766A (zh) 2013-03-01 2024-03-26 康德生物医疗有限公司 治疗线粒体疾病的方法
WO2014209905A2 (en) * 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods and compositions for detecting and diagnosing diseases and conditions

Also Published As

Publication number Publication date
ES2750258T3 (es) 2020-03-25
US20180147251A1 (en) 2018-05-31
US20160228487A1 (en) 2016-08-11
EP3626252A1 (en) 2020-03-25
JP2022116008A (ja) 2022-08-09
US9687519B2 (en) 2017-06-27
CN105407906A (zh) 2016-03-16
US12268724B2 (en) 2025-04-08
DK2961420T3 (da) 2019-10-07
WO2014134554A1 (en) 2014-09-04
JP7381652B2 (ja) 2023-11-15
HUE046924T2 (hu) 2020-03-30
JP2021098704A (ja) 2021-07-01
EP2961420B1 (en) 2019-09-11
CA2916880C (en) 2021-02-09
JP6918046B2 (ja) 2021-08-11
EP2961420A4 (en) 2016-08-17
CN115990241A (zh) 2023-04-21
US20200345803A1 (en) 2020-11-05
CN115990242A (zh) 2023-04-21
JP7072692B2 (ja) 2022-05-20
JP2019147815A (ja) 2019-09-05
US11771734B2 (en) 2023-10-03
US20240156892A1 (en) 2024-05-16
US11083771B2 (en) 2021-08-10
US11083772B2 (en) 2021-08-10
US20210401923A1 (en) 2021-12-30
EP2961420A1 (en) 2016-01-06
JP2016511259A (ja) 2016-04-14
CA2916880A1 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
JP7381652B2 (ja) バース症候群の予防または治療のための方法及び組成物
US11266709B2 (en) Methods for the regulation of matrix metalloproteinase expression
EP4397314A1 (en) Treatment of left ventricular remodeling
US20200113966A1 (en) Methods and compositions for regulating srca2a expression levels in myocardial infarction
WO2014185952A1 (en) Methods for the prevention or treatment of left ventricle remodeling
HK40019493A (en) Methods and compositions for the prevention or treatment of barth syndrome
HK1219673A1 (en) Methods and compositions for the prevention or treatment of barth syndrome
HK1219673B (en) Methods and compositions for the prevention or treatment of barth syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190301

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190419

R150 Certificate of patent or registration of utility model

Ref document number: 6518197

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250